Christopher Gilligan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christopher Gilligan has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Abd-Elsayed
Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA
27 shared publications - Timothy Ray Deer
The Spine and Nerve Center of The Virginias, Charleston, WV 25301, USA
7 shared publications Frank Huygen
Department of Anaesthesiology Erasmus Medical Center Rotterdam the Netherlands
5 shared publicationsJean-Pierre Van Buyten
AZ Niklaas Multidisciplinary Pain Center, Sint Niklaas, Belgium
4 shared publicationsJessica Jameson
4 shared publications- Peter S. Staats
National Spine and Pain Centers, Atlantic Beach, FL, USA
4 shared publications
Latest Publications
- 27 August 2026
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 3 (9)
Implementation of an AI-Triggered Rapid Response — Association with Mortality
- 27 August 2026
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 3 (9)
Implementation of an AI-Triggered Rapid Response — Association with Mortality
- 6 May 2026
- Published by Wiley in Pain Practice
- Vol. 26 (5) , e70161
Women in Pain Medicine
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-18
The American Society of Pain and Neuroscience (ASPN) Evidence-Based Consensus Recommendations on Programming and Coding Implantable Spinal Cord Stimulation Devices for Treatment of Chronic Intractable Pain
Background: The evolution of Spinal Cord Stimulation (SCS) from simple bipolar programming to sophisticated physiologic closed-loop technology has introduced significant complexity into programming and associated reimbursement coding and billing. To address these challenges, the American Society for Pain and Neuroscience (ASPN) developed this evidence-based consensus document to establish best practices for integrating advanced SCS programming into clinical workflows. Materials and Methods: A US-based expert panel in neuromodulation convened to develop consensus recommendations for traditional and modern complex programming. No international experts in neuromodulation participated in this exercise. This process informed the development of a framework that combines technological advances with improved clinical decision-making and creation of customized care plans for chronic pain patients. Results: Complex programming is defined as the adjustment of more than three stimulation parameters. However, innovations like Evoked Compound Action Potential (ECAP) dose-controlled closed-loop SCS technology provide objective neurophysiological data requiring additional physician engagement and clinical decision-making in the programming process. Objective data provide additional documentation, and when combined with traditional subjective data it ensures that clinical decisions are evidence-based and well-documented in patients’ medical history. This article reviews Current Procedural Terminology (CPT) codes and billing processes, offering clear recommendations on billing for complex programming. The framework aims to ensure that reimbursement models accurately reflect the time, resources, and expertise required for modern SCS programming while complying with coding and billing regulations. Conclusion: Current billing and reimbursement structures must be refined to recognize the additional diagnostic and therapeutic value provided by ECAP dose-controlled closed-loop therapy neural metrics. The incorporation of ECAP dose-controlled closed-loop SCS technology into routine clinical care has the potential to improve patient outcomes through comprehensive physician-led programming. This in turn will reduce the burden of chronic pain on the healthcare system by minimizing unnecessary reprogramming and emergency room visits.
- 1 January 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-18
Open AccessThe American Society of Pain and Neuroscience (ASPN) Evidence-Based Consensus Recommendations on Programming and Coding Implantable Spinal Cord Stimulation Devices for Treatment of Chronic Intractable Pain
Background: The evolution of Spinal Cord Stimulation (SCS) from simple bipolar programming to sophisticated physiologic closed-loop technology has introduced significant complexity into programming and associated reimbursement coding and billing. To address these challenges, the American Society for Pain and Neuroscience (ASPN) developed this evidence-based consensus document to establish best practices for integrating advanced SCS programming into clinical workflows. Materials and Methods: A US-based expert panel in neuromodulation convened to develop consensus recommendations for traditional and modern complex programming. No international experts in neuromodulation participated in this exercise. This process informed the development of a framework that combines technological advances with improved clinical decision-making and creation of customized care plans for chronic pain patients. Results: Complex programming is defined as the adjustment of more than three stimulation parameters. However, innovations like Evoked Compound Action Potential (ECAP) dose-controlled closed-loop SCS technology provide objective neurophysiological data requiring additional physician engagement and clinical decision-making in the programming process. Objective data provide additional documentation, and when combined with traditional subjective data it ensures that clinical decisions are evidence-based and well-documented in patients’ medical history. This article reviews Current Procedural Terminology (CPT) codes and billing processes, offering clear recommendations on billing for complex programming. The framework aims to ensure that reimbursement models accurately reflect the time, resources, and expertise required for modern SCS programming while complying with coding and billing regulations. Conclusion: Current billing and reimbursement structures must be refined to recognize the additional diagnostic and therapeutic value provided by ECAP dose-controlled closed-loop therapy neural metrics. The incorporation of ECAP dose-controlled closed-loop SCS technology into routine clinical care has the potential to improve patient outcomes through comprehensive physician-led programming. This in turn will reduce the burden of chronic pain on the healthcare system by minimizing unnecessary reprogramming and emergency room visits.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 5799-5813
Restorative Neurostimulation for Patients with Mechanical Chronic Low Back Pain and Impaired Neuromuscular Control of the Lumbar Spine | A New Treatment Paradigm
Chronic low back pain (CLBP) is a symptom of an underlying pathology. There are distinct phenotypes of CLBP, including neuropathic, nociplastic and nociceptive, or mechanical CLBP. We present a comprehensive clinical overview of restorative neurostimulation for refractory, disabling, mechanical CLBP. Impaired neuromuscular control and consequent degeneration of the multifidus muscles are implicated in the development and persistence of mechanical low back pain. Restorative neurostimulation targets these processes and aims to reverse these degenerative changes in the muscles and mechanoreceptor in the muscle spindles and, therefore, restore motor control of the multifidus muscles, playing an important role for functional stability of the lumbar spine. We detail the theory and rationale of the technology as well as appropriate patient identification and current trial evidence in this comprehensive overview of restorative neurostimulation.
- 1 November 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 5799-5813
Open AccessRestorative Neurostimulation for Patients with Mechanical Chronic Low Back Pain and Impaired Neuromuscular Control of the Lumbar Spine | A New Treatment Paradigm
Chronic low back pain (CLBP) is a symptom of an underlying pathology. There are distinct phenotypes of CLBP, including neuropathic, nociplastic and nociceptive, or mechanical CLBP. We present a comprehensive clinical overview of restorative neurostimulation for refractory, disabling, mechanical CLBP. Impaired neuromuscular control and consequent degeneration of the multifidus muscles are implicated in the development and persistence of mechanical low back pain. Restorative neurostimulation targets these processes and aims to reverse these degenerative changes in the muscles and mechanoreceptor in the muscle spindles and, therefore, restore motor control of the multifidus muscles, playing an important role for functional stability of the lumbar spine. We detail the theory and rationale of the technology as well as appropriate patient identification and current trial evidence in this comprehensive overview of restorative neurostimulation.
- Open Access
- 16 October 2025
- Published by Wiley in Pain Practice
- Vol. 25 (8) , e70094
Outcomes of the SpineJack Implant System for Cancer Patients With Pathological Fractures
- 16 October 2025
- Published by Wiley in Pain Practice
- Vol. 25 (8) , e70094
Open AccessOutcomes of the SpineJack Implant System for Cancer Patients With Pathological Fractures
- Open Access
- 16 October 2025
- Published by Wiley in Pain Practice
- Vol. 25 (8) , e70093
Objective Data From Patients With Persistent Spinal Pain Syndrome Type II Implanted With Spinal Cord Stimulator
- 16 October 2025
- Published by Wiley in Pain Practice
- Vol. 25 (8) , e70093
Open AccessObjective Data From Patients With Persistent Spinal Pain Syndrome Type II Implanted With Spinal Cord Stimulator
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 2823-2838
A Cost Effectiveness Analysis of Spinal Cord Stimulation versus Conventional Medical Management for the Treatment of Low Back Pain Using Data from DISTINCT RCT and Medical Claims from a U.S. Commercial Payer Database
Purpose: To compare the healthcare utilization (HCU) and costs for passive recharge burst Spinal Cord Stimulation (SCS) and conventional medical management (CMM) cohorts in patients with chronic low back pain (LBP) to a matched real-world cohort of similar indication. The null hypothesis is that SCS is equally or less cost-effective than CMM in treating LBP. Patients and Methods: DISTINCT is a prospective, multi-center, randomized study. Data was collected during in-clinic visits at baseline, one, three, and six months. The DISTINCT “completer cohort” included 79 DISTINCT SCS patients and 55 DISTINCT CMM patients who completed the six-month visit. An external real-world cohort (n = 71) with similar characteristics to DISTINCT CMM patients was identified from a claims database (Optum’s de-identified Market Clarity Data). Accessed data included healthcare resource utilization (HCU), pain-related medication usage, pain scale, and quality of life. HCU data covered physical therapy, chiropractic therapy, massage therapy, occupational therapy, acupuncture, injection treatments, radiofrequency ablation procedures, and opioid and anticonvulsant usage. Results: The DISTINCT study demonstrated superior outcomes in pain relief, function, and other symptoms with SCS compared to CMM in the treatment of persistent (at least 6 months) low back pain. DISTINCT SCS patients utilized fewer healthcare resources and incurred lower costs than DISTINCT CMM patients. Real-world CMM patients exhibited higher utilization of certain therapies, suggesting potential pre-crossover bias. SCS resulted in significant cost savings and improved quality of life compared to CMM. Including device costs, cost-effectiveness could be achieved within 2.7 years based on DISTINCT data. The real-world CMM arm used more high-priced interventional therapies, suggesting a pre-crossover bias in the CMM cohort. Conclusion: This analysis supports the long-term benefits and cost-effectiveness of SCS in managing chronic LBP compared to CMM.
- 1 June 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 2823-2838
Open AccessA Cost Effectiveness Analysis of Spinal Cord Stimulation versus Conventional Medical Management for the Treatment of Low Back Pain Using Data from DISTINCT RCT and Medical Claims from a U.S. Commercial Payer Database
Purpose: To compare the healthcare utilization (HCU) and costs for passive recharge burst Spinal Cord Stimulation (SCS) and conventional medical management (CMM) cohorts in patients with chronic low back pain (LBP) to a matched real-world cohort of similar indication. The null hypothesis is that SCS is equally or less cost-effective than CMM in treating LBP. Patients and Methods: DISTINCT is a prospective, multi-center, randomized study. Data was collected during in-clinic visits at baseline, one, three, and six months. The DISTINCT “completer cohort” included 79 DISTINCT SCS patients and 55 DISTINCT CMM patients who completed the six-month visit. An external real-world cohort (n = 71) with similar characteristics to DISTINCT CMM patients was identified from a claims database (Optum’s de-identified Market Clarity Data). Accessed data included healthcare resource utilization (HCU), pain-related medication usage, pain scale, and quality of life. HCU data covered physical therapy, chiropractic therapy, massage therapy, occupational therapy, acupuncture, injection treatments, radiofrequency ablation procedures, and opioid and anticonvulsant usage. Results: The DISTINCT study demonstrated superior outcomes in pain relief, function, and other symptoms with SCS compared to CMM in the treatment of persistent (at least 6 months) low back pain. DISTINCT SCS patients utilized fewer healthcare resources and incurred lower costs than DISTINCT CMM patients. Real-world CMM patients exhibited higher utilization of certain therapies, suggesting potential pre-crossover bias. SCS resulted in significant cost savings and improved quality of life compared to CMM. Including device costs, cost-effectiveness could be achieved within 2.7 years based on DISTINCT data. The real-world CMM arm used more high-priced interventional therapies, suggesting a pre-crossover bias in the CMM cohort. Conclusion: This analysis supports the long-term benefits and cost-effectiveness of SCS in managing chronic LBP compared to CMM.
- 20 May 2025
- Published by Wiley in Pain Practice
- Vol. 25 (5) , e70045
Demystifying Spinal Cord Stimulation as Not More Than a Placebo: An Evidence‐Based Perspective
- 20 May 2025
- Published by Wiley in Pain Practice
- Vol. 25 (5) , e70045
Demystifying Spinal Cord Stimulation as Not More Than a Placebo: An Evidence‐Based Perspective